{
    "ticker": "PTCT",
    "name": "Ptc Therapeutics, Inc.",
    "description": "Ptc Therapeutics, Inc. is a global biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for the treatment of rare diseases and other critical conditions. Established in 1998 and headquartered in South Plainfield, New Jersey, Ptc is dedicated to advancing the science of drug discovery and development, particularly in the areas of genetic disorders and neuromuscular diseases. The company is recognized for its pioneering work in gene therapy and protein modulation, with a portfolio that includes therapies aimed at addressing conditions such as Duchenne Muscular Dystrophy (DMD) and other rare genetic disorders. Ptc's commitment to patient-centric solutions drives its research pipeline, which includes both approved therapies and investigative treatments. The company collaborates with various stakeholders, including academic institutions, healthcare providers, and patient advocacy groups, to ensure a comprehensive approach to drug development and patient care. Ptc's mission is to transform the lives of patients by providing access to innovative therapies that address unmet medical needs worldwide.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "South Plainfield, New Jersey, USA",
    "founded": "1998",
    "website": "https://www.ptctherapeutics.com",
    "ceo": "Stuart Peltz",
    "social_media": {
        "twitter": "https://twitter.com/PtcTherapeutics",
        "linkedin": "https://www.linkedin.com/company/ptc-therapeutics"
    },
    "investor_relations": "https://investors.ptctherapeutics.com",
    "key_executives": [
        {
            "name": "Stuart Peltz",
            "position": "CEO"
        },
        {
            "name": "Seth Ettenberg",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Approved Therapies",
            "products": [
                "Translarna",
                "Emflaza"
            ]
        },
        {
            "category": "Pipeline Products",
            "products": [
                "PTC-ALD",
                "PTC-AAT"
            ]
        }
    ],
    "seo": {
        "meta_title": "Ptc Therapeutics, Inc. | Innovative Medicines for Rare Diseases",
        "meta_description": "Explore Ptc Therapeutics, Inc., a leader in biopharmaceuticals focused on developing innovative therapies for rare diseases. Learn about our mission, products, and impact.",
        "keywords": [
            "Ptc Therapeutics",
            "Biopharmaceuticals",
            "Rare Diseases",
            "Duchenne Muscular Dystrophy",
            "Gene Therapy"
        ]
    },
    "faq": [
        {
            "question": "What does Ptc Therapeutics specialize in?",
            "answer": "Ptc Therapeutics specializes in developing innovative therapies for rare diseases and genetic disorders."
        },
        {
            "question": "Who is the CEO of Ptc Therapeutics?",
            "answer": "Stuart Peltz is the CEO of Ptc Therapeutics, Inc."
        },
        {
            "question": "Where is Ptc Therapeutics headquartered?",
            "answer": "Ptc Therapeutics is headquartered in South Plainfield, New Jersey, USA."
        },
        {
            "question": "What are some of Ptc Therapeutics' main products?",
            "answer": "Ptc Therapeutics' main products include Translarna and Emflaza."
        },
        {
            "question": "When was Ptc Therapeutics founded?",
            "answer": "Ptc Therapeutics was founded in 1998."
        }
    ],
    "competitors": [
        "SRPT",
        "RARE",
        "NVS",
        "VRTX"
    ],
    "related_stocks": [
        "AMGN",
        "BMY",
        "GILD",
        "ABBV"
    ]
}